CREKA peptide-functionalized CS NPs are employed for combined chemotherapy with tumor-infarction therapy and chemotherapy via the codelivery of DOX and thrombin to tumor and tumor blood vessels overexpressing fibrin-fibronectin. This evidence concerns the gene FN1 and neoplasm.